BRIDGEWATER, N.J., Feb. 10, 2020 /PRNewswire/ -- Insmed
Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a
mission to transform the lives of patients with serious and rare
diseases, today announced that it will release its fourth quarter
and year-end financial results on Tuesday,
February 25, 2020.
Insmed management will host a conference call for investors
beginning at 8:30 a.m. ET on Tuesday,
February 25, 2020 to discuss the financial results and
provide a business update.
Shareholders and other interested parties may participate in the
conference call by dialing (888) 317-6003 (domestic) or (412)
317-6061 (international) and referencing conference ID number
3317351. The call will also be webcast live on the company's
website at www.insmed.com.
A replay of the conference call will be accessible approximately
one hour after its completion through March
3, 2020 by dialing (877) 344-7529 (domestic) or (412)
317-0088 (international) and referencing replay access code
10139238. A webcast of the call will also be archived for 90 days
under the Investor Relations section of the company's website at
www.insmed.com.
About Insmed
Insmed Incorporated is a global biopharmaceutical company on a
mission to transform the lives of patients with serious and rare
diseases. Insmed's first commercial product is ARIKAYCE®
(amikacin liposome inhalation suspension), which is approved in
the United States for the
treatment of Mycobacterium avium complex (MAC) lung disease
as part of a combination antibacterial drug regimen for adult
patients with limited or no alternative treatment options. MAC lung
disease is a rare and often chronic infection that can cause
irreversible lung damage and can be fatal. Insmed's earlier-stage
clinical pipeline includes INS1007, a novel oral reversible
inhibitor of dipeptidyl peptidase 1 with therapeutic potential in
non-cystic fibrosis bronchiectasis and other inflammatory diseases,
and INS1009, an inhaled formulation of a treprostinil prodrug that
may offer a differentiated product profile for rare pulmonary
disorders, including pulmonary arterial hypertension. For more
information, visit www.insmed.com.
Contact:
Investors:
Argot Partners
Laura Perry or Heather Savelle
(212) 600-1902
insmed@argotpartners.com
Media:
Mandy Fahey
Senior Director, Corporate Communications
Insmed
(732) 487-7468
amanda.fahey@insmed.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/insmed-to-host-fourth-quarter-and-full-year-2019-financial-results-conference-call-on-tuesday-february-25-2020-301001171.html
SOURCE Insmed Incorporated